Design, Synthesis, and Preliminary Evaluation of Doxazolidine Carbamates as Prodrugs Activated by Carboxylesterases
作者:David J. Burkhart、Benjamin L. Barthel、Glen C. Post、Brian T. Kalet、Jordan W. Nafie、Richard K. Shoemaker、Tad H. Koch
DOI:10.1021/jm060597e
日期:2006.11.30
The synthesis and tumor cell growth inhibition by doxazolidine carbamate prodrugs are reported. The carbamates were designed for selective hydrolysis by one or more human carboxylesterases to release doxazolidine (Doxaz), the formaldehyde-oxazolidine of doxorubicin that cross-links DNA to trigger cell death. Simple butyl and pentyl, but not ethyl, carbamate prodrugs inhibited the growth of cancer cells
报道了多沙唑烷氨基甲酸酯前药的合成和肿瘤细胞生长抑制。氨基甲酸酯被设计用于通过一种或多种人类羧酸酯酶选择性水解以释放多沙唑烷 (Doxaz),多柔比星的甲醛-恶唑烷交联 DNA 以引发细胞死亡。简单的丁基和戊基,但不是乙基,氨基甲酸酯前药抑制过度表达羧酸酯酶 CES1 (hCE1) 和 CES2 (hiCE) 的癌细胞的生长。相对 CES1 和 CES2 表达水平通过各自 mRNA 的逆转录,然后进行聚合酶链式反应扩增来确定。具有对氨基苯甲醇 (PABA) 自消除间隔物的更复杂结构显示出更好的生长抑制作用(对 Hep G2 肝癌细胞的 IC50=50 nM),同时对大鼠心肌细胞的毒性降低,相对于母体药物阿霉素。待进一步研究的先导化合物 4-(N-doxazolidinylcarbonyloxymethyl)phenylcarbamate 似乎在表达 CES1 和 CES2 的 Hep G2